-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IOA-244 in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IOA-244 in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IOA-244 in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)Drug Details:IOA-244 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IOA-244 in Anaplastic Large Cell Lymphoma (ALCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IOA-244 in Anaplastic Large Cell Lymphoma (ALCL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IOA-244 in Anaplastic Large Cell Lymphoma (ALCL) Drug Details:IOA-244 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IOA-244 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IOA-244 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IOA-244 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details:IOA-244 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IOA-244 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IOA-244 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IOA-244 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic LymphadenopathyDrug Details:IOA-244 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fadraciclib in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fadraciclib in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fadraciclib in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Thematic Analysis
NewGlobal Tech, Media, and Telecom (TMT) M&A Deals 2023 – Top Themes and Predictions – Thematic Intelligence
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 Theme and Predictions Report Overview Total M&A deal value in the technology, media, and telecom (TMT) sector declined 46% in 2023, compared to the previous year. Software and services accounted for over 48% share of the total M&A deal value in 2023. The ‘Global Tech, Media, And Telecom (TMT) M&A Deals 2023 Theme and Predictions Report’ analyzes the top disruptive themes that drove M&A activity in the technology, media, and telecom (TMT)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talazoparib in Urethral Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talazoparib in Urethral Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talazoparib in Urethral Cancer Drug Details: Talazoparib (Talzenna, Tarzena) is an anti-neoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Taladegib in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Taladegib in Solid Tumor Drug Details: Taladegib (LY-2940680) is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ITI-333 in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ITI-333 in Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ITI-333 in Pain Drug Details: ITI-333 is under development for the treatment of...